The FDA has approved Novartis’ Tasigna for pediatric Ph+CML patients, resulting in a six month pediatric exclusivity period after primary patent expiry. This narrows the HyNap-Nilo patent window, but as income is far into the future and the increased patient population makes up for lost value, the net effect is zero.